Depression and Anxiety symptoms in Patients with Liver Cirrhosis Before, During and After the COVID-19 Pandemic: Prevalence and Impact on Hepatic Decompensation

Abstract Background: The COVID-19 pandemic substantially increased the burden of anxiety and depression, particularly among patients with chronic diseases. However, data on the prevalence of these symptoms in patients with liver cirrhosis (LC) during and after the pandemic remain limited. We evaluated the prevalence of anxiety and depressive symptoms in LC patients before, during, and after the pandemic and assessed their impact on hepatic decompensation. Methods: In this single-centre cohort study, consecutive inpatients with LC, inpatients without liver disease (non-LD) and hospital employees as healthy controls (HC) were recruited during three matched calendar windows: April–June 2019, 2020 and 2024. Symptoms of Depression and anxiety were assessed on admission using the Patient Health Questionnaire-4 (PHQ-4). Patients with a known psychiatric disease, alcohol misuse or acute alcoholic hepatitis were excluded. The 2020 LC cohort was followed for 12 months; the primary endpoint was hepatic decompensation requiring readmission. Results: Of 978 patients screened, a total of n = 603 were included (294 LC [110/129/55]; 309 non-LD [104/101/104]), plus 153 HC; 47% were female, median age 61 years. In LC, a positive screen for depressive symptoms rose from 3.6% in 2019 to 25.4% in 2020 and returned to 3.5% in 2024; anxiety symptoms followed the same pattern (4.5%, 24.4% and 1.8%). During the pandemic both were more frequent in LC than in non-LD patients (25.4% vs. 3.9% and 24.4% vs. 3.8%; both p < 0.005) or in HC. Of 96 LC patients followed for 12 months, 29 (31%) developed hepatic decompensation. Depressive symptoms were associated with decompensation in univariable analysis (HR 2.23, 95% CI 1.13–4.40), after adjustment, only Child-Pugh score remained independently associated with the endpoint (HR 1.9, 95% CI 1.2–3.1). Conclusions: The COVID 19 pandemic was associated with a marked increase in anxiety and depressive symptoms in patients with liver cirrhosis, whereas no comparable rise occurred in either control group. Depressive symptoms were associated with subsequent hepatic decompensation over the following year. Routine screening, using an easy to apply test, can help to identify patients at risk during future health care crises and therefore should enable preventive interventions in susceptible groups.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-16
DOI
https://doi.org/10.21203/rs.3.rs-11260986/v1
Primary Topic
COVID-19 and Mental Health
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Depression and Anxiety symptoms in Patients with Liver Cirrhosis Before, During and After the COVID-19 Pandemic: Prevalence and Impact on Hepatic Decompensation

Thomas Horvatits, Johannes Kluwe, Sven Pischke, Thomas Theo Brehm et al.
2 links
Research Square
COVID-19 and Mental Health
preprint

Depression and Anxiety symptoms in Patients with Liver Cirrhosis Before, During and After the COVID-19 Pandemic: Prevalence and Impact on Hepatic Decompensation

Thomas Horvatits, Johannes Kluwe, Sven Pischke, Thomas Theo Brehm, Karoline Horvatits, Greta Priebe, Ansgar W. Lohse, Thorben W. Fründt, Samuel Huber
preprint en

Abstract

Abstract Background: The COVID-19 pandemic substantially increased the burden of anxiety and depression, particularly among patients with chronic diseases. However, data on the prevalence of these symptoms in patients with liver cirrhosis (LC) during and after the pandemic remain limited. We evaluated the prevalence of anxiety and depressive symptoms in LC patients before, during, and after the pandemic and assessed their impact on hepatic decompensation. Methods: In this single-centre cohort study, consecutive inpatients with LC, inpatients without liver disease (non-LD) and hospital employees as healthy controls (HC) were recruited during three matched calendar windows: April–June 2019, 2020 and 2024. Symptoms of Depression and anxiety were assessed on admission using the Patient Health Questionnaire-4 (PHQ-4). Patients with a known psychiatric disease, alcohol misuse or acute alcoholic hepatitis were excluded. The 2020 LC cohort was followed for 12 months; the primary endpoint was hepatic decompensation requiring readmission. Results: Of 978 patients screened, a total of n = 603 were included (294 LC [110/129/55]; 309 non-LD [104/101/104]), plus 153 HC; 47% were female, median age 61 years. In LC, a positive screen for depressive symptoms rose from 3.6% in 2019 to 25.4% in 2020 and returned to 3.5% in 2024; anxiety symptoms followed the same pattern (4.5%, 24.4% and 1.8%). During the pandemic both were more frequent in LC than in non-LD patients (25.4% vs. 3.9% and 24.4% vs. 3.8%; both p < 0.005) or in HC. Of 96 LC patients followed for 12 months, 29 (31%) developed hepatic decompensation. Depressive symptoms were associated with decompensation in univariable analysis (HR 2.23, 95% CI 1.13–4.40), after adjustment, only Child-Pugh score remained independently associated with the endpoint (HR 1.9, 95% CI 1.2–3.1). Conclusions: The COVID 19 pandemic was associated with a marked increase in anxiety and depressive symptoms in patients with liver cirrhosis, whereas no comparable rise occurred in either control group. Depressive symptoms were associated with subsequent hepatic decompensation over the following year. Routine screening, using an easy to apply test, can help to identify patients at risk during future health care crises and therefore should enable preventive interventions in susceptible groups.

Research Square
University Medical Center Hamburg-Eppendorf (DE)
Universitätsklinikum Hamburg-Eppendorf
Good health and well-being
COVID-19 and Mental Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon